Offering rebates has been a pricing strategy for manufacturers of brand-named prescription drugs for decades. The explosion of rebate value has happened over the last 10-12 years as pharmacy benefit managers (PBMs)
In this final part of the series, we will dive into PBM performance and support—answering questions about how PBMs gauge plan effectiveness and provide support to stakeholders.
In this second part of our series, we delve into the inner workings of PBMs, answering questions about what happens after a patient fills a prescription, how benefits are effectively managed, and the strategic approaches PBMs utilize.
Employer groups often engage brokers, consultants, or third-party administrators to assist in evaluating and selecting pharmacy benefit plans to offer their plan participants. While these professionals handle much of the detailed work
Industry reports have shown the percentage of healthcare dollars spent on pharmacy continues to rise, jumping from 21% to 27% since 2021.¹ With even greater trends projected in the coming years,
Plan sponsors and their partners lean on their pharmacy benefit manager (PBM) to facilitate the implementation process. However, some PBMs have better processes than others. That is why working with a trusted PBM is crucial.
Patient assistance dollars from Pharma exploded in recent years as companies worked to get patients on their medications and use this funding as a political talking point for patient access.
Pharmacy Benefit Managers (PBMs) contract with employers, health plans, and other plan sponsors, incorporating language related to prescription drug definitions, rebate guarantees, pricing, and more.
National CooperativeRx’s team of experts has developed a tool that provides a detailed analysis of each of our innovative clinical programs and their estimated savings unique to each pharmacy benefit plan.
As a member-owned Cooperative that strives to provide services that enhance the value and quality of members’ pharmacy benefits, a decision was made to bring specialty prior authorizations (PA) in-house, effective January 1, 2023.
First launched in 2003, Humira has experienced more than two decades of unprecedented marketplace dominance. A mainstay of treatment for several autoimmune conditions, National CooperativeRx’s members spend more on this drug than any other under the pharmacy benefit.
As the year of the dragon readies to swoop in, the year of the rabbit hops to an end. Astrological signs aside, the future of